From the dermatology foundationSerious infections in hospitalized patients with psoriasis in the United States
Section snippets
Methods
The 2002 to 2012 Nationwide Inpatient Sample (NIS) was analyzed. The NIS is sponsored by the Healthcare Cost and Utilization Project (HCUP) of the Agency for Healthcare Research and Quality (AHRQ).10 Each year of NIS contains an approximately 20% stratified representative sample of all hospitalizations in the United States. Sample weights were created by NIS that factored the sampling design of hospitals. These sample weights were needed to provide representative estimates of hospital
Results
Overall, there were 87,039,711 discharges captured in the NIS between the years 2002 and 2012. There were 2738 primary admissions for psoriasis and 184,508 secondary diagnoses of psoriasis (weighted: 13,051 and 885,115, respectively). Patients with psoriasis (age 59.9 ± 0.2 years) were older than patients without psoriasis (age 47.9 ± 0.1 years), 47.5% female, and mostly white (Table I). Serious infections represented 28.2% of all hospitalizations in patients with psoriasis, but only 21.0% of
Discussion
This study demonstrated that serious infections were significantly higher in prevalence for inpatients with psoriasis than for inpatients without psoriasis. Psoriasis was associated with cellulitis, herpes simplex virus infection, fungal infections, infectious arthritis, viral infections, tuberculosis, osteomyelitis, meningitis, encephalitis, septicemia, enterocolitis, MRSA, MSSA, and C difficile infection even after adjusting for demographic factors. The infections associated with highest
References (22)
- et al.
Psoriasis prevalence among adults in the United States
J Am Acad Dermatol
(2014) - et al.
The pathogenic role of tissue-resident immune cells in psoriasis
Trends Immunol
(2007) Innate and adaptive immunity and the pathophysiology of psoriasis
J Am Acad Dermatol
(2006)An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis
Clin Ther
(2003)- et al.
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials
J Am Acad Dermatol
(2011) - et al.
Potential misclassification of patients with psoriasis in electronic databases
J Am Acad Dermatol
(2008) - et al.
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
J Am Acad Dermatol
(2012) - et al.
The Inpatient Burden of Psoriasis in the United States
J Am Acad Dermatol
(2016) - et al.
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004
J Am Acad Dermatol
(2009) - et al.
Psoriasis: dysregulation of innate immunity
Br J Dermatol
(2005)
Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
Br J Dermatol
Cited by (39)
Serum Lipids and Risk of Incident Psoriasis: A Prospective Cohort Study from the UK Biobank Study and Mendelian Randomization Analysis
2022, Journal of Investigative DermatologyCitation Excerpt :The characteristics of psoriasis are keratinocyte hyperproliferation and dysregulated T helper 17 immune response (Karczewski et al., 2016). The processes of psoriasis are chronic and often accompanied by other comorbidities such as metabolic syndrome, psychological disorders, and infections, which may change the choice of treatment and management compared with single diseases (Homayoon et al., 2020; Hsu et al., 2016; Pannu and Rosmarin, 2021). The relationships between psoriasis and comorbidities have received widespread attention.
Association of herpes zoster and chronic inflammatory skin disease in US inpatients
2021, Journal of the American Academy of DermatologyPsoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey
2021, Journal of the American Academy of DermatologyCitation Excerpt :These findings are consistent with previous studies reporting an increased rate of pneumonia-specific mortality5,8,34,35 and an increased risk of malignancy.5,8,25,29,36 The increased risk of severe infections and malignancy has been attributed to systemic immune dysregulation inherent to psoriasis25,35-38 and the immunosuppressive actions of systemic and biologic therapies.25,36,39 In combination, our findings suggest that the higher use of systemic and biologic therapies for the treatment of psoriasis in the United States may be partially responsible for the difference in the mortality burden between our study and European cohorts.
Predictors of hospital readmission in United States adults with psoriasis
2020, Journal of the American Academy of DermatologyCitation Excerpt :Frequent readmissions are not limited to psoriasis, as a recent study of US hospitalizations demonstrated high rates of readmission among patients admitted with skin disorders in general7 and atopic dermatitis8 in particular. Our findings suggest readmission is associated with skin infection, which is consistent with a previous study which found that serious infections in general and skin infections in particular were associated with higher odds of hospitalization for psoriasis.9 Increased skin infections may be secondary to poor control of the psoriasis vs adverse effects of treatments.
Risk of acute infections in patients with psoriasis: A nationwide population-based cohort study
2020, Journal of the American Academy of Dermatology
This publication was made possible with support from the Agency for Healthcare Research and Quality, grant number K12HS023011, the Dermatology Foundation. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Conflicts of interest: None declared.